

# VILIN BIO MED LIMITED

VALUATION REPORT FOR VALUATION OF EQUITY SHARE FOR THE PROPOSED PREFERENTIAL ALLOTMENT U/S SECTION 62(1)(C) OF THE COMPANIES ACT, 2013 AND REGULATION 164 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018.

**A. N. GAWADE**

FCA, RV (IBBI)

**Registered Valuer**

Securities or Financial Assets

Regn No. IBBI/ RV/05/2019/10746



# A. N. GAWADE

FCA, RV (IBBI)

7, Saraswati Heights,  
Behind Café Goodluck,  
Deccan Gymkhana, Pune 411004  
Phone No. Ph. 7722063311  
Email: ang@angca.com

## Registered Valuer

Securities or Financial Assets

Regn No. IBBI/ RV/05/2019/10746

Date: January 24, 2026

To,

**The Board of Directors**

**Vilin Bio Med Limited**

**Plot No. 43, H. No. 8-2-269/S/43,**

**Sagar Co-op Housing Society Ltd,**

**Road No. 2, Banjara Hills, Hyderabad, 500034**

**Sub: Submission of Addendum to Valuation Report for the issue of Equity Share for the proposed preferential allotment u/s Section 62(1)(c) of the Companies Act, 2013 and Regulation 164, Regulation 166A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.**

Dear Sir/s,

I have been engaged by the Management of Vilin Bio Med Limited (hereinafter referred to as “Company “or “Vilin Bio”) to assess fair value of Equity Share for the proposed preferential allotment under Sec 62(1)(c) of the Companies Act 2013 and Regulation 164 and Regulation 166A of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 since the Company is Listed in SME Platform of National Stock Exchange of India Limited (NSE). The Company is registered under the Companies Act, 1956 (CIN: L24230TG2005PLC046689) and its registered office is at Plot No. 43, H. No. 8-2-269/S/43, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills, Hyderabad, 500034.

I have relied on the financial statements given by the management of the company and have not assessed the merits or legality of the transaction. Our report is not some advice on the transaction and should not be used as the basis of investment. In case of material changes in the financial statements or financial position of the company, the values may change significantly. Our valuation conclusion will not necessarily be the price at which the actual transaction will take place.



Based on the information provided by the management, I have arrived at the “Fair Value” (“Valuation” or “Value”) of the Company as of the relevant date i.e., 09/01/2026. It should be noted that the valuation engagement is purely an analytical exercise based on the information and documents given to us. Based on our assessment, the value of the shares of the Company is arrived at INR 23.50 per equity share. The detailed valuation report including computation of fair value of the Equity share of the Company has been attached in subsequent pages.

Thanking You,  
Yours Faithfully,

Anandkumar  
Narayan Gawade

Digitally signed by  
Anandkumar Narayan Gawade  
Date: 2026.01.24 16:10:38  
+05'30'

Mr. Anandkumar Gawade,  
Registered Valuer  
Reg. No. IBBI/RV/05/2019/10746  
UDIN: **26110752BRTVTN7491**



## Contents

<b>Scope and Purpose of this report and appointing authority:</b> .....	5
<b>Key Dates:</b> .....	6
<b>Identity of the valuer and other experts involved in the valuation:</b> .....	6
<b>Declaration of Independence of Valuer and Financial Interest:</b> .....	6
<b>Sources of Information:</b> .....	6
<b>Inspections and/or Investigations undertaken:</b> .....	6
<b>Introduction and background of Company:</b> .....	7
<b>Current Capital Structure of the Company:</b> .....	7
<b>Valuation Approaches:</b> .....	6
1) Market Approach: .....	8
2) Income Approach:.....	9
3) Cost Approach: .....	10
<b>Procedures adopted in carrying out the valuation and valuation standards followed:</b> .....	10
<b>Gratitude:</b> .....	11
<b>Conclusion:</b> .....	<b>Error! Bookmark not defined.</b>
<b>Limitations, Caveats and Disclaimers:</b> .....	13



### Scope and Purpose of this report and appointing authority:

Mr. Anandkumar Gawade, Registered Valuer has been requested by the Board of Directors of the Company to submit a valuation report recommending the fair value of equity shares of the Company for proposed preferential allotment. Equity shares of the Company are frequently traded on the stock exchange as per SEBI ICDR Regulations.

Our report is subject to the scope of limitations detailed hereinafter. As such the report is said to be read in totality, not in parts, in conjunction with the relevant documents referred to therein.

### **The relevant extracts of the Companies Act, 2013 is as under:**

*62. Further issue of share capital—(1) Where at any time, a company having a share capital proposes to increase its subscribed capital by the issue of further shares, such shares shall be offered—*

*(c) to any persons, if it is authorised by a special resolution, whether or not those persons include the persons referred to in clause (a) or clause (b), either for cash or for a consideration other than cash, if the price of such shares is determined by the valuation report of a registered valuer subject to such conditions as may be prescribed.*

### **The relevant extracts of Regulation 164 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 is as under:**

*If the equity shares of the issuer have been listed on a recognised stock exchange for a period of 90 trading days] or more as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following:*

*a. the 90 trading days' volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date; or*

*b. the 10 trading days] volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.*

### **The relevant extracts of Regulation 166A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 is as under:**

*"Any preferential issue, which may result in a change in control or allotment of more than five per cent. of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price:*

*Provided that the floor price, in such cases, shall be higher of the floor price determined under sub-regulation (1), (2) or (4) of regulation 164, as the case may be, or the price determined under the valuation report from the independent registered valuer or the price determined in accordance with the provisions of the Articles of Association of the issuer, if applicable:*

*Provided further that if any proposed preferential issue is likely to result in a change in control of the issuer, the valuation report from the registered valuer shall also cover guidance on control premium, which shall be computed over and above the price determined in terms of the first proviso...."*



### Key Dates:

For this assignment of valuation, the following shall be the key dates:

- a. **Valuation Date:** The value of the company should be the value as of the relevant date i.e., January 09, 2026 considering the latest available financials as disclosed to the stock exchange and the trading data preceding the relevant date.
- b. **Report Date:** Our original valuation report has been submitted as of January 10, 2026.
- c. **Addendum Report Date:** The Addendum has been submitted as on January 24, 2026.

### Identity of the valuer and other experts involved in the valuation:

Valuation is carried out by me, i.e. Anandkumar Gawade, Registered valuer under Class Securities or Financial Assets vide Registration No. IBBI/RV/05/2019/10746. I am also Practicing Chartered Accountant since 2002 vide MRN 110752. There were no other experts involved in the carrying out the process of valuation of Securities. I am allowed to carry out the said valuation as per the rules.

### Declaration of Independence of Valuer and Financial Interest:

I hereby declare that I am independent of the Subject Company for valuation and has not been under any direct or indirect influence, which may affect the valuation exercise. I also state that I have no financial interest in the Subject Company for valuation, except earlier services for valuation if any. I also confirm that this engagement shall be following the model Code of Conduct issued by IBBI vide Valuation Rule.

### Sources of Information:

The following information has been received from the Management of the company:

- Audited Financial statements of the Company for the period for FY 2025, FY 2024, FY 2023 and period ended September 30, 2025.
- Quantity of shares traded and Traded turnover of equity shares of the Company on National Stock Exchange of India Limited (NSE).
- I have also accessed public documents as available from external sources such as mca.gov.in to better understand and assess the value of the business.
- I have also obtained necessary explanations and information, which I believed were relevant to the present exercise, from the executives and representatives of the company.

### Inspections and/or Investigations undertaken:

- I have verified the industry in which the company is operating and the performance of the industry.
- I have applied all the appropriate techniques for arriving at the valuation.
- MOA, AOA of the Company, and other ROC Documents.
- Oral information for various clarifications.
- Stock exchange trading information.



### Introduction and Background of Company:

Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products

CIN	L24230TG2005PLC046689
Company Name	VILIN BIO MED LIMITED
ROC Code	ROC Hyderabad
Registration Number	046689
Company Category	Company limited by Shares
Company SubCategory	Non-govt company
Class of Company	Public
Authorised Capital (Rs)	15,00,00,000
Paid up Capital (Rs)	13,95,00,000
Date of Incorporation	29/06/2005
Registered Address	Plot No. 43, H. No. 8-2-269/S/43, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills, Hyderabad, 500034.

(source: [www.mca.in](http://www.mca.in))

### Current Capital Structure of the Company:

Particulars	Amount in Rs.
<b>Issued, Subscribed and Paid up Share Capital</b>	
1,39,50,000 Equity shares of Rs. 10/- each	13,95,00,000



### Valuation Approaches:

There are three main valuation approaches. They are all based on the economic principles of price equilibrium, anticipation of benefits or substitution. The goal in selecting valuation approaches and methods for an asset is to find the most appropriate method under the particular circumstances. No one method is suitable in every possible situation. The main valuation approaches are:

#### 1) **Market Approach:**

The Market Approach provides an indication of value by comparing the asset with identical or comparable (that is similar) *assets* for which price information is available. The Market Approach should be applied and afforded significant weight under the following circumstances:

- The subject asset has recently been sold in a transaction appropriate for consideration under the basis of value,
- The subject asset or substantially similar assets are actively publicly traded, and/or
- There are frequent and/or recent observable transactions in substantially similar assets.

There are some of the limitations to the Market Approach which are as follows:

- It is difficult to identify transactions or companies that are comparable. There is usually a lack of a sufficient number of comparable companies or transactions.
- It is less flexible compared to other methods.

The method raises questions on how much data is available and how good the data is. The company is a listed company and shares of the company are traded frequently in the Market since, the traded turnover of the company during the 240 trading days preceding the relevant date is more than 10% of its total number of Shares.

Total no. of shares of Vilin Bio	1,39,50,000
10% of total no. of shares of Vilin Bio	13,95,000
<b>Total traded shares on Stock Exchange</b>	<b>32,52,000</b>

**Given the shares are frequently traded, I have applied the Market Approach to valuation as per the method prescribed under SEBI ICDR Regulation 164 as follows:**

I have considered data of higher of the following under this approach:

Sl. No.	Parameters	Value (in INR)
i	a. the 90 trading days volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date (Annexure 1)	23.50
ii	b. the 10 trading days volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date (Annexure 2)	22.39
	<b>Higher of the above</b>	<b>23.50</b>

**As per calculation, Market price is arrived at INR 23.50.**



## 2) Income Approach:

The Income Approach provides an indication of value by converting future cash flow to single current value. Under the Income Approach, the value of an asset is determined by reference to the value of income, cash flow or cost savings generated by the asset.

The Income Approach should be applied and afforded *significant weight* under the following circumstances:

- The income-producing ability of the asset is the critical element affecting value from a participant perspective, and/or
- Reasonable projections of the amount and timing of future income are available to the subject asset, but there are few, if any, relevant markets comparable.

A fundamental basis for the Income Approach is that investors expect to receive a return on their investments and that such a return should reflect the perceived level of risk in the investment.

One of the advantages is that the Income Approach has over the other two approaches is that it is more flexible in addressing firms or assets that are in different stages of the life cycle. This is because this approach factors in varying operating conditions over the projected period. The Income Approach is also able to cater to the differing investment or ownership needs of the buyer and seller, by measuring risks through its discount or capitalization rate, or by including cost synergies in its projections.

I have used Profit Earning Capitalization Method (PECV), here I have capitalized the weighted average profit of past three years (FY-2025, 2024 and 2023) and half year period ending September 30, 2025 by using a capitalization rate of 10.69% (calculation attached below).

*Amount in Lakhs (Unless otherwise mentioned)*

<b>Profit Earning Capacity Value</b>					
<b>Calculation of Value per Share</b>					
<b>Year</b>	<b>PBT</b>	<b>Weight</b>	<b>PAT</b>	<b>Value x Weight</b>	<b>Average PAT</b>
2022-2023	178.16	1.00	124.50	124.50	
2023-2024	22.52	1.00	16.24	16.24	
2024-2025	30.58	1.00	22.35	22.35	
September 30, 2025	19.38	0.50	15.17	7.59	
<b>Weighted Average Profit After Tax</b>					<b>48.76</b>
Capitalisation Rate					9.03%
<b>Capitalised Equity Value</b>					<b>540.24</b>
No. of Equity Shares					1,39,50,000
<b>Value Per Share ( in INR)</b>					<b>3.87</b>



**Capitalization Rate is calculated as follows:**

COE assumptions	Values	Source
Risk free rate, Rf	6.72%	Risk Free Rate based on 10-year Government Bond Rate) *
Expected Return, Rm	13.69%	Based on historic rolling returns of Sensex
Market equity risk premium over risk free rate	6.97%	Rm-Rf
Beta	0.76	Industry Beta from published data of Professor Ashwath Damodaran
Additional risk premium	2.00%	To account for higher risk as the Company is in high growth phase.
<b>Adjusted Cost of equity, Ke</b>	<b>14.03%</b>	Computation
Long Term Growth rate	5.00%	
<b>Capitalisation Rate %</b>	<b>9.03%</b>	Ke Adjusted with Long Term Growth

\*Source: <https://www.ccilindia.com/RiskManagement/SecuritiesSegment/Pages/ZCYC.aspx>

**3) Cost Approach:**

The Cost Approach provides an indication of value using the economic principle that a buyer will pay no more for an asset than the cost to obtain an *asset* of equal utility, whether by purchase or by construction, unless undue time, inconvenience, risk, or other factors are involved. The Approach provides an indication of value by calculating the current replacement or reproduction cost of an asset and making deductions for physical deterioration and all other relevant forms of obsolescence. The Cost Approach *should* be applied and afforded *significant weight* under the following circumstances:

- Partners would be able to recreate an asset with substantially the same utility as the subject asset, without regulatory or legal restrictions, and the asset could be recreated quickly enough that a participant would not be willing to pay a significant premium for the ability to use the subject asset immediately.
- The asset is not directly income generating and the unique nature of the asset makes using an Income Approach or Market Approach unfeasible and/or
- The basis of value being used is fundamentally based on replacement cost, such as replacement value.

I have calculated the amount of Net Worth in the books of the company as on September 30, 2025.

*Amount in Lakhs (Unless otherwise mentioned)*

<b>Calculation of Book Value as on 30-09-2025</b>		
<b>Particulars</b>	<b>Amount</b>	<b>Amount</b>
Share Capital	1,395.00	
Add : Reserve & Surplus	926.52	2,321.52
<b>Book Value</b>		<b>2,321.52</b>
No. of Equity Shares (Face Value@10)		1,39,50,000
<b>Value Per Share (Rs.)</b>		<b>16.64</b>



**Procedures adopted in carrying out the valuation and valuation standards followed:**

- Business valuation has been carried out using approaches and methodologies given under IVS 105 “Valuation Approaches and Methods’ and in compliance with SEBI ICDR Regulations
- Business valuation is carried out by Market Price Method.
- Scope of this report is provided by complying the IVS 101 “Scope of Work”.
- Investigations undertaken for carrying out the valuation is done as per IVS 102 “Investigations and Compliance”. Sufficient Evidence has been assembled by means of inspection, enquiry and analysis.

**Gratitude:**

I am grateful to the Management for making information and particulars available to me, often at a short notice, without which this assessment would not have been concluded in a time-bound manner.

**Value of Vilin Bio Med Limited**

Since, the Company proposed to issue Equity shares to some of the allottees, in terms of the provisions of Regulation 164 of SEBI ICDR 2018, as amended upto date, the company requires Valuation of its Equity shares for issuance on preferential basis. Accordingly, the minimum price shall be higher of the floor price determined under sub-regulation (1), (2) or (4) of regulation 164 or the price determined by the Valuer or the price determined in accordance with the provisions of the Articles of Association of the issuer.

Additionally, any preferential issue, which may result in a change in control or allotment of more than five percent. of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price.

Therefore, for the evaluation of fair valuation, I, being an independent Valuer, have considered best reasonable judgment to value the equity shares through Market Approach (Price calculated in terms of sub-regulation (1), (2) or (4) of regulation 164 of SEBI ICDR 2018) since, the Articles of Association of the Company are silent on the determination of a floor price/minimum price of the shares issued on preferential basis.

<b>Calculation of Fair Value</b>			
<b>Valuation Method</b>	<b>Value (In INR)</b>	<b>Weights</b>	<b>Value x Weight</b>
Market Value	23.50	33.33%	7.83
Net Asset Value Method	16.64	33.33%	5.55
Profit Earning Capacity Value	3.87	33.33%	1.29
		100.00%	<b>14.67</b>
<b>Fair Value</b>			<b>14.67</b>

Note: Since, in the instant case, as mentioned in the relevant extracts of Regulation 166A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the proposed preferential issue is not likely to result in a change in control of the issuer nor shares than 5% are being issued as per information given to me by the management of the Company, hence, control premium has not been considered.



**Conclusion:**

As per Regulation 164 (1) of SEBI Preferential Issue Regulations, value per share of the company is arrived at INR 23.50 and the weighted average Fair Value as per table above is INR 14.67. Therefore, as per Regulation 164(1) of SEBI Preferential Issue Regulations, the fair value of the equity shares of the company for the purpose the transaction will be higher of the two and hence INR 23.50 can be considered as fair value of the equity shares of the company.

In the light of above, and on the consideration of all relevant factors as discussed and outline hereinabove, the price of the equity shares of Vilin Bio Med Limited to be allotted pursuant to the preferential issue shall not be less than INR 23.50/- per Share as calculated under SEBI ICDR Regulation 164.



## Limitations, Caveats and Disclaimers:

### **1. Restriction on use of Valuation Report**

This document has been prepared for the purposes stated herein and should not be relied upon for any other purpose. My client is the only authorized user of this report and is restricted for the purpose indicated in the engagement letter. This restriction does not preclude the client from providing a copy of the report to third-party advisors whose review would be consistent with the intended use and the Regulations. I/I do not take any responsibility for the unauthorized use of this report.

### **2. Responsibility of RV**

I owe responsibility to only to the authority/client that has appointed me/us under the terms of the engagement letters. I will not be liable for any losses, claims, damages or liabilities arising out of the actions taken, omissions or advice given by any other person. In no event shall I be liable for any loss, damages, cost or expenses arising in any way from fraudulent acts, misrepresentations or wilful default on part of the client or companies, their directors, employees or agents.

### **3. Accuracy of Information**

While my work has involved an analysis of financial information and accounting records, my engagement does not include an audit in accordance with generally accepted auditing standards of the client existing business records. Accordingly, I express no audit opinion or any other form of assurance on this information.

### **4. Post Valuation Date Events**

The user to which this valuation is addressed should read the basis upon which the valuation has been done and be aware of the potential for later variations in value due to factors that are unforeseen at the valuation date. Due to possible changes in market forces and circumstances, this valuation report can only be regarded as relevant as at the valuation date.

### **5. No Responsibility to the Actual Price of the subject asset if sold or transferred/ exchanged**

The actual market price achieved may be higher or lower than my estimate of value (or value range of value) depending upon the circumstances of the transaction (for example the competitive bidding environment), the nature of the business (for example the purchaser's perception of potential synergies). The knowledge, negotiating ability and motivation of the buyers and sellers and the applicability of a discount or premium for control will also affect actual market price achieved. Accordingly, my valuation conclusion will not necessarily be the price at which actual transaction will take place.

### **6. Reliance on the representations of the owners/clients, their management and other third parties**

The client/owner and its management/representatives warranted to us that the information they supplied was complete, accurate and true and correct to the best of their knowledge. I have relied upon the representations of the owners/clients, their management and other third parties concerning the financial data, operational data and maintenance schedule of all plant-machinery-equipment-tools-vehicles, real estate investments and any other investments in tangible assets except as specifically stated to the contrary in the report. I shall not be liable for any loss, damages, cost or expenses arising from fraudulent acts, misrepresentations, or wilful default on part of the companies, their directors, employee or agents.



**7. No procedure performed to corroborate information taken from reliable external sources**

I have relied on data from external sources also to conclude the valuation. These sources are believed to be reliable and therefore, I assume no liability for the truth or accuracy of any data, opinions or estimates furnished by others that have been used in this analysis. Where I have relied on data, opinions or estimates from external sources, reasonable care has been taken to ensure that such data has been correctly extracted from those sources and /or reproduced in its proper form and context.

**8. Compliance with relevant laws**

The report assumes that the company/business/asset complies fully with relevant laws and regulations applicable in its area of operations and usage unless otherwise stated, and that the companies/business/assets will be managed in a competent and responsible manner. Further, as specifically stated to the contrary, this report has given no consideration to matters of a legal nature, including issues of legal title and compliance with local laws, and litigations and other contingent liabilities that are not recorded/reflected in the balance sheet/fixed assets register provided to us.

**9. Multiple factors affecting the Valuation Report:**

The valuation report is tempered by the exercise of judicious discretion by the RV and judgment taking into account the relevant factors. There will always be several factors, e.g., management capability, present and prospective competition, yield on comparable securities, market sentiment, etc. which may not be apparent from the Balance Sheet but could strongly influence the value.

**10.** Future services including but not limited to Testimony or attendance in courts/ tribunals/ authorities for the opinion of value in the Valuation Report.

**11.** I am fully aware that based on the opinion of value expressed in this report, I may be required to give testimony or attend court / judicial proceedings with regard to the subject assets, although it is out of scope of the assignment, unless specific arrangements to do so have been made in advance, or as otherwise required by law. In such event, the party seeking my evidence in the proceedings shall bear the cost/professional fee of attending court / judicial proceedings and my tendering evidence before such authority shall be under the applicable laws.

**12.** While my work has involved an analysis of trading data, my engagement does not include an audit in accordance with generally accepted auditing standards of the client existing business records. Accordingly, I assume no responsibility and make no representations with respect to the accuracy or completeness of any information provided by and on behalf of you and the client. my report is subject to the scope and limitations detailed hereinafter. As such the report is to be read in totality, and not in parts, in conjunction with the relevant documents referred to herein and in the context of the purpose for which it is made.

**13.** The valuation of companies and businesses is not a precise science and the conclusions arrived at in many cases will be subjective and dependent on the exercise of individual judgment.

**14.** The actual market price achieved may be higher or lower than my estimate of depending upon the circumstances of the transaction (for example the competitive bidding environment), the nature of the business (for example the purchaser's perception of potential synergies). The knowledge, negotiating ability and motivation of the buyers and sellers and the applicability of a discount or premium for control will also affect actual market price achieved. Accordingly, my valuation conclusion will not necessarily be the price



at which any agreement proceeds. The final transaction price is something on which the parties themselves have to agree. I also emphasize that my opinion is not the only factor that should be considered by the parties in agreeing the transaction price.

15. An analysis of such nature is necessarily based on the prevailing stock market, financial, economic and other conditions in general and industry trends in particular as in effect on, and the information made available to us as of, the date hereof. Events occurring after the date hereof may affect this report and the assumptions used in preparing it, and I do not assume any obligation to update, revise or reaffirm this Report.
16. The ultimate analysis will have to be tempered by the exercise of judicious discretion by the RV and judgment taking into account the relevant factors. There will always be several factors, e.g., management capability, present and prospective competition, yield on comparable securities, market sentiment, etc. which may not be apparent from the face of the Balance Sheet but could strongly influence the value.
17. In the course of the valuation, I was provided with both written and verbal information. I have however, evaluated the information provided to us by the Company through broad inquiry, analysis and review but have not carried out a due diligence or audit of the information provided for the purpose of this engagement. My conclusions are based on the assumptions, forecasts and other information given by/on behalf of the Company.
18. I am independent of the client/company and have no current or expected interest in the Company or its assets. The fee paid for my services in no way influenced the results of My analysis.
19. My report is meant for the purpose mentioned above and should not be used for any purpose other than the purpose mentioned therein. The Report should not be copied or reproduced without obtaining My prior written approval for any purpose other than the purpose for which it is prepared.
20. The information provided by the management is believed to be true and reliable to the best of my knowledge, I do not make any representations or warranties, express or implied, as to the accuracy or completeness of such information.
21. No investigation of the company's claim to title of the assets has been made for the purpose of this valuation and their claim to such rights has been assumed to be valid. My report is not, nor should it be construed, as I am certifying the compliance with the provisions of any law including Company and Taxation laws or as regards any legal, accounting or taxation implications or issues.
22. I have no obligation to update this report because of events or transactions occurring subsequent to the date of this report.
23. Valuation analysis are specific to the date of this report. A valuation of this nature involves consideration of various factors including those impacted by prevailing stock market trends in general and industry trends in particular. As such, my valuation results are, to a significant extent, subject to continuance of current trends beyond the date of report. I, however, have no obligation to update this report for events, trends, transactions occurring subsequent to the date of this report. This report is prepared as per Indian Laws and Rules.



24. I owe no responsibility neither accept any liability to any third party in relation to issue of this report for any false or incorrect information given to me or anything beyond my control.

*Thanking You*

*End of Report*



**Annexures:**

**Annexure 1: the 90 trading days volume weighted average price of the Company on the SME Platform of National Stock Exchange of India Limited (NSE) preceding the relevant date.**

DATE	VWAP	VOLUME	VALUE
08-Jan-26	25.25	16,000	4,04,000
07-Jan-26	23.5	16,000	3,76,000
06-Jan-26	22.63	8,000	1,81,000
05-Jan-26	21.88	12,000	2,62,600
02-Jan-26	20.9	4,000	83,600
01-Jan-26	19.95	4,000	79,800
31-Dec-25	20.33	12,000	2,44,000
29-Dec-25	20.05	8,000	1,60,400
23-Dec-25	20.38	8,000	1,63,000
19-Dec-25	20.53	12,000	2,46,400
18-Dec-25	20.05	12,000	2,40,600
17-Dec-25	19.85	8,000	1,58,800
16-Dec-25	19.48	8,000	1,55,800
15-Dec-25	19.7	12,000	2,36,400
08-Dec-25	19.5	4,000	78,000
04-Dec-25	19.28	28,000	5,39,800
03-Dec-25	20.15	4,000	80,600
02-Dec-25	20.32	20,000	4,06,400
01-Dec-25	21.2	4,000	84,800
27-Nov-25	20.2	4,000	80,800
26-Nov-25	21.13	8,000	1,69,000
25-Nov-25	22.34	20,000	4,46,800
24-Nov-25	22.81	20,000	4,56,200
21-Nov-25	22.65	4,000	90,600
18-Nov-25	22.23	16,000	3,55,600
17-Nov-25	22.8	12,000	2,73,600
14-Nov-25	22.46	52,000	11,67,800
13-Nov-25	23.6	4,000	94,400
12-Nov-25	24.83	8,000	1,98,600
11-Nov-25	24.39	68,000	16,58,600
07-Nov-25	25.21	20,000	5,04,200
04-Nov-25	26.21	16,000	4,19,400
03-Nov-25	25.3	4,000	1,01,200
31-Oct-25	26.33	12,000	3,16,000
27-Oct-25	25.2	4,000	1,00,800
24-Oct-25	26.5	4,000	1,06,000
20-Oct-25	27.03	8,000	2,16,200



17-Oct-25	27.95	4,000	1,11,800
16-Oct-25	26.8	4,000	1,07,200
15-Oct-25	25.32	20,000	5,06,400
14-Oct-25	24.33	24,000	5,83,800
10-Oct-25	25.5	8,000	2,04,000
09-Oct-25	24.3	4,000	97,200
07-Oct-25	25.55	4,000	1,02,200
06-Oct-25	24.76	16,000	3,96,200
03-Oct-25	25.07	12,000	3,00,800
01-Oct-25	24.78	8,000	1,98,200
29-Sep-25	25.73	12,000	3,08,800
26-Sep-25	26.65	12,000	3,19,800
25-Sep-25	26.74	16,000	4,27,800
23-Sep-25	25.67	12,000	3,08,000
22-Sep-25	25.15	16,000	4,02,400
17-Sep-25	25.7	12,000	3,08,400
15-Sep-25	25.2	16,000	4,03,200
12-Sep-25	24.6	4,000	98,400
10-Sep-25	23.45	4,000	93,800
05-Sep-25	23.48	12,000	2,81,800
04-Sep-25	24.65	4,000	98,600
03-Sep-25	25.34	16,000	4,05,400
02-Sep-25	26	4,000	1,04,000
<b>Total 90 Trading Days</b>		<b>7,28,000</b>	<b>1,71,06,000</b>
<b>A) Volume Weighted Average Price (90 days)</b>		<b>23.50</b>	



**Annexure 2: the 10 trading days volume weighted average price of the Company on the SME Platform of National Stock Exchange of India Limited (NSE) preceding the relevant date.**

DATE	VWAP	VOLUME	VALUE
08-Jan-26	25.25	16,000	4,04,000
07-Jan-26	23.5	16,000	3,76,000
06-Jan-26	22.63	8,000	1,81,000
05-Jan-26	21.88	12,000	2,62,600
02-Jan-26	20.9	4,000	83,600
01-Jan-26	19.95	4,000	79,800
31-Dec-25	20.33	12,000	2,44,000
29-Dec-25	20.05	8,000	1,60,400
<b>Total 10 Trading Days</b>		<b>80,000</b>	<b>17,91,400</b>
<b>B) Volume Weighted Average Price (90 days)</b>		<b>22.39</b>	

